Market Overview

UPDATE: Benchmark Initiates BioCLinica with Buy, $8 PT as Possible M&A Target

Related BIOC
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois
Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy

Benchmark initiates its coverage on BioClinica (NASDAQ: BIOC) with a Buy rating and a price target of $8.

Benchmark says, "Last week we spent a day in Philadelphia at the Drug Information Association tradeshow, which was held June 24-28. This event highlights services to the pharmaceutical industry including eClinical software vendors and CROs. Conference attendance and the corporate events appeared notably lighter than in years past but we were pleasantly surprised that generally, firms are growing, profitable and carry an optimistic outlook. In addition to healthy sector business dynamics, we sense that further M&A activity could support sector valuation. We feel BioClinica is an excellent buy now at 12.1x our forecast current year $0.40 nonGAAP EPS, or 10.1x, excluding $0.77 per share in cash."

BIOC closed at $4.80 a share on Monday.

Latest Ratings for BIOC

Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy
Aug 2015H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Initiation Intraday Update Analyst Ratings


Related Articles (BIOC)

View Comments and Join the Discussion!